Tag: Harvoni

CTAC Resource – Harvoni & Holkira Pak coverage in Canada

CTAC is pleased to share with you a preview of the treatment access information that will be contained in our soon to be launched Treatment Access Map (TxMAP).  Using data pulled from the TxMAP database we have created this one-page resource that outlines the public drug coverage under provincial and territorial formularies for Harvoni and… Read more »

The number of BC PharmaCare covered hep C treatments has been increasing and so has the information gathered by the Hepatitis C Treatment Information Project. The Hep C TIP now has new pages dedicated to BC’s PharmaCare and the treatments that are covered by it. These pages are: Treatments Targeted Genotype Ribavirin with Pegylated Interferon… Read more »

CATIE HepCinfo Update 6.6

New warning issued for serious heart problems when Harvoni or sofosbuvir is taken with amiodarone The U.S. Food and Drug Administration (FDA) is warning that serious slowing of the heart rate (symptomatic bradycardia) can occur when the drug amiodarone, which is used to treat an irregular heartbeat, is taken together either with Harvoni or with… Read more »

CATIE’s HepCInfo Updates 6.2

New and Noteworthy Screening Canadians born between 1945 and 1965 could be cost effective According to a modelling study, one-time screening for people 25 to 64 or 45 to 64 years of age could be cost-effective, reported researchers in the Canadian Medical Association Journal. For both age ranges the researchers modelled four options: No screening… Read more »

CATIE’s HepCInfo Update 5.24

New and Noteworthy Harvoni cures 98% of Hep C and HIV co-infected participants with genotype 1 virus 98% of Hep C and HIV co-infected participants with genotype 1 virus who took Harvoni (ledipasvir + sofosbuvir) during a 12-week clinical trial were cured, reported researchers at the American Association for the Study of Liver Diseases (AASLD)… Read more »